Lakcid Intima

Lactobacillus gasseri DSM 14869 and Lactobacillus rhamnosus DSM 14870, the active ingredients in Lakcid Intima, are a probiotic drug class presented as a vaginal probiotic formulation for vaginal use. It helps restore normal vaginal microbiota and may aid in preventing bacterial vaginosis and supporting treatment of yeast infections in women.

GNH USA supplies Lakcid Intima as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Lakcid Intima is a vaginal probiotic that acts on the normal vaginal microbiome to promote health and prevent infection. - Restoration of normal vaginal flora: re‑establishes a balanced lactobacilli population after disturbance. - Prevention of bacterial vaginosis: reduces overgrowth of pathogenic bacteria. - Adjunctive therapy for vaginal yeast infections: supports conventional antifungal treatment by maintaining a healthy microbial environment.

Common Side Effects: - Mild vaginal irritation or burning sensation. - Increased vaginal discharge that is clear or whitish. - Transient itching or tingling. - Temporary change in odor. - Slight abdominal cramping. - Mild headache (rare).

Serious or Rare Side Effects: - Allergic reaction such as rash, swelling, or difficulty breathing. - Severe vaginal inflammation or ulceration. - Systemic infection (e.g., bacteremia) in immunocompromised patients. - Persistent foul odor despite treatment. - Persistent fever or chills. - Unexplained pelvic pain.

Before using Lakcid Intima, consider the following precautions: - Pregnancy: consult a healthcare professional before use. - Breastfeeding: seek medical advice prior to administration. - Allergy: avoid if known hypersensitivity to Lactobacillus species. - Concurrent antibiotic therapy: may diminish probiotic effectiveness. - Use only as directed: follow prescriber or product instructions. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lakcid Intima may interact with other agents that affect vaginal flora.

Major Interactions (Avoid): - Intravaginal antibiotics that eradicate lactobacilli: may nullify probiotic benefit. - Systemic immunosuppressants in severely immunocompromised patients: increased infection risk.

Moderate Interactions (Monitor Closely): - Oral broad‑spectrum antibiotics: may reduce colonisation of probiotic strains. - Hormonal contraceptives: monitor for any change in vaginal symptoms. - Other vaginal products (douches, spermicides): may interfere with probiotic activity.